H.C. Wainwright lowered the firm’s price target on Aprea Therapeutics (APRE) to $1.20 from $4 and keeps a Buy rating on the shares. The firm cites the “significant dilution” from yesterday’s financing through pre-funded warrants and warrant to buy common shares for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE: